Welcome to our dedicated page for Takeda Pharm SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK) on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily furnished on Form 20-F and Form 6-K as a foreign private issuer. Takeda prepares its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) and uses these filings to report semi-annual and annual results, management guidance and material developments in its business.
Recent Form 6-K submissions include English translations of Takeda’s semi-annual securities report and earnings report (Kessan Tanshin) for the six-month period ended September 30, 2025. These documents present revenue by business area (Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, Neuroscience and Other) and by geographic region, along with operating profit, net profit, cash flow information and explanations of non-IFRS core measures such as core revenue, core operating profit and core EPS. They also discuss factors affecting performance, including generic erosion of specific products, foreign exchange impacts and changes in product mix.
Takeda’s 6-K filings additionally furnish press releases that describe key R&D and strategic events, such as Phase 3 data for zasocitinib (TAK-279) in plaque psoriasis, longer-term VERIFY and THRIVE results for rusfertide in polycythemia vera, portfolio decisions like discontinuation of cell therapy efforts, and revised forecasts for FY2025 revenue and profit. These exhibits provide context on how clinical outcomes, impairments of intangible assets and strategic partnerships influence Takeda’s financial outlook.
Through Stock Titan, users can review Takeda’s SEC filings as they are posted, while AI-powered tools can help summarize lengthy IFRS financial reports, highlight changes in management guidance, and surface important disclosures related to pipeline programs, impairments, capital allocation and regional performance. This makes it easier to understand how Takeda’s global biopharmaceutical operations and late-stage pipeline are reflected in its official U.S. regulatory documents.
Takeda Pharmaceutical held its 149th Annual General Meeting of Shareholders on June 25, 2025, where several key resolutions were passed. The meeting addressed the company's performance for FY2024 (April 1, 2024 to March 31, 2025).
Key resolutions approved include:
- Approval of a year-end dividend of 98 JPY per share
- Re-election of ten Directors not serving on the Audit and Supervisory Committee, including CEO Christophe Weber and seven External Directors
- Approval of executive bonuses totaling up to 460 million JPY for two eligible Directors (excluding overseas Directors and External Directors)
The meeting also reviewed the Business Report, Consolidated Financial Statements, and Unconsolidated Financial Statements, along with audit results from the Accounting Auditor and Audit and Supervisory Committee. This filing demonstrates Takeda's commitment to corporate governance and shareholder transparency.